Single-dose injectable nanovaccine-in-hydrogel for robust immunotherapy of large tumors with abscopal effect
Science Advances · 14.07.2023 · 9 (28)
DOI: 10.1126/sciadv.ade6257 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 14.07.2023. Verfasst von Furong Cheng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Translational Medicine Center, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou 510260, China. Hauptthemen laut MEDLINE: Hydrogels, Neoplasms. Die Arbeit wurde bisher 80-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NINDS NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Current cancer immunotherapy [e.g., immune checkpoint blockade (ICB)] only benefits small subsets of patients, largely due to immunosuppressive tumor microenvironment (TME). In situ tumor vaccination can reduce TME immunosuppression and thereby improve cancer immunotherapy. Here, we present single-dose injectable (nanovaccines + ICBs)-in-hydrogel (NvIH) for robust immunotherapy of large tumors with abscopal effect. NvIH is thermo-responsive hydrogel co-encapsulated with ICB antibodies and novel polymeric nanoparticles loaded with three immunostimulatory agonists for Toll-like receptors 7/8/9 (TLR7/8/9) and stimulator of interferon genes (STING). Upon in situ tumor vaccination, NvIH undergoes rapid sol-to-gel transformation, prolongs tumor retention, sustains the release of immunotherapeutics, and reduces acute systemic inflammation. In multiple poorly immunogenic tumor models, single-dose NvIH reduces multitier TME immunosuppression, elicits potent TME and systemic innate and adaptive antitumor immunity with memory, and regresses both local (vaccinated) and distant large tumors with abscopal effect, including distant orthotopic glioblastoma. Overall, NvIH holds great potential for tumor immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Translational Medicine Center, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou 510260, China.
- Department of Pharmaceutics and Center for Pharmaceutical Engineering and Sciences, Institute for Structural Biology and Drug Discovery, School of Pharmacy, The Developmental Therapeutics Program, Massey Cancer Center,…
- Center for Translational Medicine, Precision Medicine Institute, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.
- Department of Pharmaceutical Sciences, College of Pharmacy, Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA.
ORCID-Profile: Furong Cheng, Ting Su, Shuibin Lin, Weisheng Guo, Guizhi Zhu
Förderung
- NIGMS NIH HHS
- NINDS NIH HHS
- NCI NIH HHS
- NCATS NIH HHS
- NIAID NIH HHS
Zitieren
APA
Cheng, F., Su, T., Zhou, S., Liu, X., Yang, S., Lin, S., Guo, W., & Zhu, G. (2023). Single-dose injectable nanovaccine-in-hydrogel for robust immunotherapy of large tumors with abscopal effect. Science Advances, 9(28). https://doi.org/10.1126/sciadv.ade6257
Vancouver
Cheng F, Su T, Zhou S, Liu X, Yang S, Lin S, et al. Single-dose injectable nanovaccine-in-hydrogel for robust immunotherapy of large tumors with abscopal effect. Science Advances. 2023;9(28). doi:10.1126/sciadv.ade6257
BibTeX
@article{Cheng2023,
author = {Cheng, Furong and Su, Ting and Zhou, Shurong and Liu, Xiang and Yang, Suling and Lin, Shuibin and Guo, Weisheng and Zhu, Guizhi},
title = {Single-dose injectable nanovaccine-in-hydrogel for robust immunotherapy of large tumors with abscopal effect},
journal = {Science Advances},
year = {2023},
volume = {9},
number = {28},
doi = {10.1126/sciadv.ade6257}
}
EUVIMED